SCHEMBL1012529

SCHEMBL1012529

CCOC(=O)c1cnc(NC2C3CN(C(=O)OC(C)(C)C)CC32)nc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ATM Q13315 1/20 0.44
NPSR1 Q6W5P4 2/20 0.41
LMNA P02545 2/20 0.41
MEN1 O00255 1/20 0.41
ALDH1A1 P00352 1/20 0.41
GAA P10253 1/20 0.41
KMT2A Q03164 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
MAPT P10636 1/20 0.41
JAK3 P52333 2/20 0.40
GPR119 Q8TDV5 2/20 0.39
TP53 P04637 1/20 0.39
POLB P06746 1/20 0.39
GABRA5 P31644 1/20 0.38
THRB P10828 1/20 0.37
F13A1 P00488 1/20 0.37
TGM2 P21980 1/20 0.37
TGM1 P22735 1/20 0.37
GLA P06280 1/20 0.37
P2RY12 Q9H244 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1012011 0.85 P2RY12 (0.42) MEN1ALDH1A1GAAKMT2AP2RY12
SCHEMBL12723444 0.83 ACACB (0.40) MEN1ALDH1A1GAAKMT2AMAPT
SCHEMBL17762744 0.83 MAPT (0.53) ATMNPSR1LMNAMEN1ALDH1A1
SCHEMBL31271007 0.79 GPR119 (0.56) ATMNPSR1LMNAMEN1ALDH1A1
SCHEMBL1011608 0.78 ACACB (0.46) ATMNPSR1LMNAMEN1ALDH1A1
SCHEMBL24992878 0.77 ATM (0.46) ATMNPSR1MAPTGPR119
SCHEMBL12939727 0.77 GRIN2B (0.52) ATMNPSR1LMNAMEN1ALDH1A1
SCHEMBL1010754 0.77 PCSK9 (0.38) MEN1KMT2ASMN1; SMN2MAPTPOLB
SCHEMBL12480371 0.76 GPR119 (0.56) ATMMAPTGPR119
SCHEMBL16644394 0.75 ATM (0.46) ATMNPSR1LMNAMEN1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7932246-B2 Histone deacetylase inhibitors CHROMA THERAPEUTICS LTD. (GB) 2011-04-26 US disclosed
US-7932246-B2 Histone deacetylase inhibitors CHROMA THERAPEUTICS LTD. (GB) 2011-04-26 US disclosed
EP-1881977-B1 HISTONE DEACETYLASE INHIBITORS CHROMA THERAPEUTICS LTD (GB) 2011-01-05 EP disclosed
US-20100152155-A1 Histone Deacetylase Inhibitors CHROMA THERAPEUTICS LTD. (GB) 2010-06-17 US disclosed
US-20100152155-A1 Histone Deacetylase Inhibitors CHROMA THERAPEUTICS LTD. (GB) 2010-06-17 US disclosed
EP-1881977-A1 HISTONE DEACETYLASE INHIBITORS Chroma Therapeutics Limited (GB) 2008-01-30 EP disclosed
WO-2006123121-A1 HISTONE DEACETYLASE INHIBITORS CHROMA THERAPEUTICS LTD (GB) 2006-11-23 WO disclosed
WO-2006123121-A1 HISTONE DEACETYLASE INHIBITORS CHROMA THERAPEUTICS LTD (GB) 2006-11-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100152155-A1 Histone Deacetylase Inhibitors HDAC1, HDAC2, HDAC11 ATM 3870/4885NPSR1 3160/4885LMNA 775/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.